Abstract
The introduction of Sandimmun® (ciclosporin) into immunosuppressive therapy has improved the results of organ transplantation with respect to patient survival, graft survival and the main post-transplant complications [5, 6, 16, 26], and the adverse reaction profile of this potent immunosuppressive agent has been established [7]. However, long-term safety experience is still limited. To broaden knowledge in this respect, a long-term safety follow-up, primarily of bone marrow and renal transplant recipients treated with Sandimmun, has been initiated. Preliminary data of this ongoing investigation from renal transplant recipients, who provide the bulk of the information, are presented here.
We are indebted to all investigators who are participating in this ongoing long-term safety survey, and to Miss Götz for processing the data
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beveridge T, Krupp P, McKibbin C (1984) Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy. Lancet 1:788
Birkeland SA (1983) Malignant tumors in renal transplant patients. The Scandia transplant material. Cancer 51:1571–1575
Borel JF, Bauer C, Gubler HU et al. (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6:468–475
Borel JF (1984) Animal experiments with ciclosporin. Triangle 23: 3/4, 153
Caine RY, White DJG, Evans DB et al. (1981) Cyclosporin A in cadaveric organ transplantation. Br Med J 282:934
Canadian Multicentre Transplant Study Group (1983) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809–815
Cohen DJ, Loertscher R, Rubin MF et al. (1984) Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann Intern Med 101:667–682
Handelsman DJ, McDowell IFW, Caterson ID (1984) Ovarian function after renal transplantation: comparison on cyclosporin A with azathioprine and prednisone combination regimens. Br J Obstet Gynaecol 91:802–807
Handelsman DJ, McDowell IFW, McDowell W et al. (1984) Testicular function after renal transplantation: comparison of Cyclosporin A with azathioprine and prednisone combination regimes. Clin Nephrol 22: No. 3, 144–148
Hess AD (1985) Effect of interleukin 2 on the immunosuppressive action of cyclosporine. Transplantation 39:62–68
Jacobs C, Brunner FP, Brynger H et al. (1981) Malignant diseases in patients treated by dialysis and transplantation in Europe. Transplant Proc 13:729–732
Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15:446–453
Keown PA, Stiller CR, Ulan RA et al. (1981) Immunological and pharmacological monitoring in the clinical use of cyplosporin A. Lancet 1:686–689
Kinlen LJ, Sheil AGR, Peto J, Doll R (1979) Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 2:1461 –1466
Mangal AK, Growe GH, Sinclair M et al. (1984) Acquired hemolytic anemia due to Side Effects and Safety of Sandimmun in Long-term Treatment of Transplant Patients 49 “auto”-anti-A or “auto”-anti-B induced by group 0 homograft in renal transplant recipients. Transfusion 24:201–205
Merion RM, David MD, White DJG et al. 22. (1984) Cyclosporine: Five years’ experience in cadaveric renal transplantation. N Engl J Med 310:148–154
Mihatsch JM, Thiel G, Ryffel B (1985) 23. Ciclosporin-associated Nephropathy. In: Schindler R (ed) Ciclosporin in Autoimmune Diseases. 1st International Symposium, Basle, March 18–20, 1985. Springer, Berlin 24. Heidelberg New York Tokyo, p 50
Najarian JS, Ferguson RM, Sutherland DER et al. (1983) A prospective trial of the ef- 25. ficacy of cyclosporine in renal transplantation at the University of Minnesota. Transplant Proc 15: No. 1, 438–441
Oyer PE, Stinson EB, Jamieson SW et al. (1984) Cyclosporine in cardiac transplan- 26. tation: A 2Y2 year follow-up. In: B. D. Kahan, Cyclosporine, Vol. 1, Biological Activity and Clinical Applications. Grune and Stratton, Orlando, p 330–336 27.
Penn I (1970) Malignant tumors in organ transplant recipients. Springer, Berlin
Price CP, Deam SM, Calvin J (1983) Serum alkaline phosphatase isoenzyme in patients on cyclosporin A following renal transplantation. Clin Biochem 16, No. 5, Abstr. C314, A25
Reece IJ, Okereke OUJ, Painvin GA et al. (1984) Infection in cyclosporine-immunosuppressed cardiac allograft recipients. Heart Transplant 3:239–242
Sheil AGR, Mahony JF, Horvath JS et al. (1981) Cancer following successful cadaveric donor renal transplantation. Transplant Proc 13:733–735
Sheil AGR (1984) Cancer in organ transplant recipients: part of an induced immune deficiency syndrome. Br Med J 288:659–661
Thiel G, Harder F, Loertscher R, et al. (1983) Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation. Klin Wochenschr 61:991 —1000
van Buren CT, Rechner SM, Kerman RH et al. (1984) Cyclosporine improves outcome in high-risk cadaveric renal allograft recipients. Transplant Proc 16:1162–1166
Vanrenterghem Y, Gresele P, Roels L et al. (1985) Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1:999–1002
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Sandoz Ltd, Basle
About this paper
Cite this paper
Krupp, P., Timonen, P., Gülich, A. (1985). Side Effects and Safety of Sandimmun® in Long-term Treatment of Transplant Patients. In: Schindler, R. (eds) Ciclosporin in Autoimmune Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70607-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-70607-3_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-70609-7
Online ISBN: 978-3-642-70607-3
eBook Packages: Springer Book Archive